Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Esperion Therapeutics, Inc. to Con...
January 16 2016 - 6:30AM
The securities litigation law firm of Brower Piven, A Professional
Corporation, announces that a class action lawsuit has been
commenced in the United States District Court for the Eastern
District of Michigan on behalf of purchasers of Esperion
Therapeutics, Inc. (Nasdaq:ESPR) (“Esperion” or the “Company”)
common stock during the period between August 18, 2015 and
September 28, 2015, inclusive (the “Class Period”). Investors
who wish to become proactively involved in the litigation have
until March 14, 2016 to seek appointment as lead plaintiff.
If you have suffered a loss from investment in
common stock purchased on or after August 18, 2015 and held through
the revelation of negative information during and/or at the end of
the Class Period, as described below, and would like to learn more
about this lawsuit and your ability to participate as a lead
plaintiff, without cost or obligation to you, please visit our
website at
http://www.browerpiven.com/currentsecuritiescases.html. You
may also request more information by contacting Brower Piven either
by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. No class has yet been certified in the above
action. Members of the Class will be represented by the lead
plaintiff and counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you
and the Class, you must apply to be appointed lead plaintiff and be
selected by the Court. The lead plaintiff will direct the
litigation and participate in important decisions including whether
to accept a settlement for the Class in the action. The lead
plaintiff will be selected from among applicants claiming the
largest loss from investment in Company common stock during the
Class Period. Brower Piven also encourages anyone with
information regarding the Company’s conduct during the period in
question to contact the firm, including whistleblowers, former
employees, shareholders and others.
The complaint accuses the defendants of
violations of the Securities Exchange Act of 1934 by virtue of the
defendants’ failure to disclose during the Class Period that there
was no clear path to approval for ETC-1002, and that the U.S Food
and Drug Administration (“FDA”) had encouraged the Company to
initiate a cardiovascular outcomes trial (“CVOT”), the completion
of which could be necessary prior to approval of ETC–1002.
According to the complaint, following the
September 28, 2015 disclosure that Esperion reversed course about
having a clear regulatory path for the development and approval of
ETC-1002, and by revealing that the FDA had actually encouraged the
Company to initiate promptly a cardiovascular outcomes trial that
may be necessary prior to approval, the value of Esperion shares
declined significantly.
Attorneys at Brower Piven have extensive
experience in litigating securities and other class action cases
and have been advocating for the rights of shareholders since the
1980s. If you choose to retain counsel, you may retain Brower
Piven without financial obligation or cost to you, or you may
retain other counsel of your choice. You need take no action
at this time to be a member of the class.
CONTACT:
Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
hoffman@browerpiven.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024